Jan 5 (Reuters) - Halozyme Therapeutics Inc said its lead drug to treat a late form of pancreated cancer met the main goal in a mid-stage study, sending its shares soaring in premarket trading.
The study population showed a statistically significant increase in progression-free survival, the company said.
Pancreatic cancer is the third-leading cause of cancer-related death in the United States.
Halozyme’s shares were up 44 percent at $15.40 in trading before the opening bell on Thursday. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Ted Kerr)